Recombinant human interferon alpha-2a increases the antitumor activity of 5-fluorouracil on human colon carcinoma xenograft Co-4 without any change in 5-FU pharmacokinetics

S. Kase, T. Kubota, M. Watanabe, Toshiharu Furukawa, H. Tanino, T. H. Kuo, Y. Saikawa, T. Teramoto, M. Kitajima

研究成果: Article

5 引用 (Scopus)

抄録

We investigated the modulating effect of recombinant human interferon alpha-2a (IFN-α) on the antitumor activity of 5-fluorouracil (5-FU) against a human colon carcinoma xenograft (Co-4) in nude mice with reference to changes in the pharmacokinetic pattern of 5-FU. Mice bearing Co-4 received 5-FU ip at a dose of 90 mg/kg once with or without IFN-α, which was administered sc at a dose of 60.000 IU/mouse daily for 7 days before 5-FU treatment. When the area under the curve (AUC) and peak plasma concentration (Cmax) of 5-FU with or without IFN-α were measured as pharmacokinetic parameters, the pharmacokinetics of 5-FU was not changed by IFN-α administration. This result suggests that the modulating effect of IFN-α on 5-FU does not involve augmentation of 5-FU pharmacokinetic parameters.

元の言語English
ページ(範囲)153-155
ページ数3
ジャーナルAnticancer Research
15
発行部数1
出版物ステータスPublished - 1995

Fingerprint

Heterografts
Fluorouracil
Colon
Pharmacokinetics
Carcinoma
interferon alfa-2a
Nude Mice
Area Under Curve

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

これを引用

Recombinant human interferon alpha-2a increases the antitumor activity of 5-fluorouracil on human colon carcinoma xenograft Co-4 without any change in 5-FU pharmacokinetics. / Kase, S.; Kubota, T.; Watanabe, M.; Furukawa, Toshiharu; Tanino, H.; Kuo, T. H.; Saikawa, Y.; Teramoto, T.; Kitajima, M.

:: Anticancer Research, 巻 15, 番号 1, 1995, p. 153-155.

研究成果: Article

Kase, S. ; Kubota, T. ; Watanabe, M. ; Furukawa, Toshiharu ; Tanino, H. ; Kuo, T. H. ; Saikawa, Y. ; Teramoto, T. ; Kitajima, M. / Recombinant human interferon alpha-2a increases the antitumor activity of 5-fluorouracil on human colon carcinoma xenograft Co-4 without any change in 5-FU pharmacokinetics. :: Anticancer Research. 1995 ; 巻 15, 番号 1. pp. 153-155.
@article{8a220988e33f439082cc099228df01a0,
title = "Recombinant human interferon alpha-2a increases the antitumor activity of 5-fluorouracil on human colon carcinoma xenograft Co-4 without any change in 5-FU pharmacokinetics",
abstract = "We investigated the modulating effect of recombinant human interferon alpha-2a (IFN-α) on the antitumor activity of 5-fluorouracil (5-FU) against a human colon carcinoma xenograft (Co-4) in nude mice with reference to changes in the pharmacokinetic pattern of 5-FU. Mice bearing Co-4 received 5-FU ip at a dose of 90 mg/kg once with or without IFN-α, which was administered sc at a dose of 60.000 IU/mouse daily for 7 days before 5-FU treatment. When the area under the curve (AUC) and peak plasma concentration (Cmax) of 5-FU with or without IFN-α were measured as pharmacokinetic parameters, the pharmacokinetics of 5-FU was not changed by IFN-α administration. This result suggests that the modulating effect of IFN-α on 5-FU does not involve augmentation of 5-FU pharmacokinetic parameters.",
keywords = "5-fluorouracil, Human colon carcinoma, Interferon alpha",
author = "S. Kase and T. Kubota and M. Watanabe and Toshiharu Furukawa and H. Tanino and Kuo, {T. H.} and Y. Saikawa and T. Teramoto and M. Kitajima",
year = "1995",
language = "English",
volume = "15",
pages = "153--155",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "1",

}

TY - JOUR

T1 - Recombinant human interferon alpha-2a increases the antitumor activity of 5-fluorouracil on human colon carcinoma xenograft Co-4 without any change in 5-FU pharmacokinetics

AU - Kase, S.

AU - Kubota, T.

AU - Watanabe, M.

AU - Furukawa, Toshiharu

AU - Tanino, H.

AU - Kuo, T. H.

AU - Saikawa, Y.

AU - Teramoto, T.

AU - Kitajima, M.

PY - 1995

Y1 - 1995

N2 - We investigated the modulating effect of recombinant human interferon alpha-2a (IFN-α) on the antitumor activity of 5-fluorouracil (5-FU) against a human colon carcinoma xenograft (Co-4) in nude mice with reference to changes in the pharmacokinetic pattern of 5-FU. Mice bearing Co-4 received 5-FU ip at a dose of 90 mg/kg once with or without IFN-α, which was administered sc at a dose of 60.000 IU/mouse daily for 7 days before 5-FU treatment. When the area under the curve (AUC) and peak plasma concentration (Cmax) of 5-FU with or without IFN-α were measured as pharmacokinetic parameters, the pharmacokinetics of 5-FU was not changed by IFN-α administration. This result suggests that the modulating effect of IFN-α on 5-FU does not involve augmentation of 5-FU pharmacokinetic parameters.

AB - We investigated the modulating effect of recombinant human interferon alpha-2a (IFN-α) on the antitumor activity of 5-fluorouracil (5-FU) against a human colon carcinoma xenograft (Co-4) in nude mice with reference to changes in the pharmacokinetic pattern of 5-FU. Mice bearing Co-4 received 5-FU ip at a dose of 90 mg/kg once with or without IFN-α, which was administered sc at a dose of 60.000 IU/mouse daily for 7 days before 5-FU treatment. When the area under the curve (AUC) and peak plasma concentration (Cmax) of 5-FU with or without IFN-α were measured as pharmacokinetic parameters, the pharmacokinetics of 5-FU was not changed by IFN-α administration. This result suggests that the modulating effect of IFN-α on 5-FU does not involve augmentation of 5-FU pharmacokinetic parameters.

KW - 5-fluorouracil

KW - Human colon carcinoma

KW - Interferon alpha

UR - http://www.scopus.com/inward/record.url?scp=0029001096&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029001096&partnerID=8YFLogxK

M3 - Article

C2 - 7733626

AN - SCOPUS:0029001096

VL - 15

SP - 153

EP - 155

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 1

ER -